TCDA - Tricida, Inc.
| Previous Close | 34.84 |
| Open | 35.09 |
| Bid | 34.80 x 1000 |
| Ask | 34.88 x 900 |
| Day's Range | 34.51 - 35.59 |
| 52 Week Range | 19.43 - 44.30 |
| Volume | 328,372 |
| Avg. Volume | 315,287 |
| Market Cap | 1.736B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.21 |
| Earnings Date | Nov 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.60 |
- Business Wire
Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
- Simply Wall St.
Did Tricida, Inc. (NASDAQ:TCDA) Insiders Buy Up More Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Tricida, Inc. (TCDA)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Business Wire
Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs. Dr. Faust, who initially joined Tricida as a consultant in September 2019, will lead the strategic development and implementation of Tricida’s medical education, publications and disease awareness activities as the company prepares for the potential launch of veverimer in 2020.
- TEST Business Wire Releases
Tricida to Present at the Evercore Annual Global Healthcare Conference
Tricida to Present at the Evercore Annual Global Healthcare Conference
- Business Wire
Tricida Announces Third Quarter 2019 Financial Results
FDA Accepts New Drug Application for Veverimer
- Business Wire
Tricida Announces FDA Acceptance of New Drug Application for Veverimer
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for veverimer under the Accelerated Approval Program. In its correspondence, FDA also stated that no filing review issues were identified.
- Business Wire
Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019
Tricida, Inc. today announced that it will report its third quarter 2019 financial results after the close of market on Thursday, November 14, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Tricida, Inc. (TCDA)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- Business Wire
Tricida to Host Investor Day on October 15, 2019
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will host its inaugural Investor Day on October 15, 2019 from 8:30 a.m. to 11:30 a.m. Eastern Time in New York, NY. The Tricida management team will provide a comprehensive overview of the Company’s commercialization strategy and market opportunity for veverimer in the treatment of metabolic acidosis in patients with CKD.
- Business Wire
Tricida Announces Multiple Data Presentations on Metabolic Acidosis to be Given at ASN Kidney Week 2019
Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer , a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with chronic kidney disease , announced today multiple presentations on metabolic acidosis that will be given at the upcoming American Society of Nephrology Kidney Week 2019 meeting taking place ...
Motley FoolTricida, Inc. (TCDA) Q2 2019 Earnings Call Transcript
TCDA earnings call for the period ending June 30, 2019.
- Simply Wall St.
Does Tricida's (NASDAQ:TCDA) Share Price Gain of 35% Match Its Business Performance?
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better...
- Simply Wall St.
Should Tricida (NASDAQ:TCDA) Be Disappointed With Their 35% Profit?
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
- Insider Monkey
Here’s What Hedge Funds Think About Tricida, Inc. (TCDA)
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
- Business Wire
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that The Lancet published online detailed results from its long-term, Phase 3, multicenter, parallel, randomized, blinded, placebo-controlled trial, TRCA-301E, in 196 patients with CKD and metabolic acidosis. “This new data highlights the value of treating metabolic acidosis in patients with CKD,” said Donald E. Wesson, M.D., M.B.A., Professor of Medicine at Texas A&M Health Science Center College of Medicine in Dallas, TX, lead investigator of the study and primary author of The Lancet paper.
- Zacks
Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour
Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour
- Zacks
4 Stocks Set to Pop on New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- Business Wire
Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Tricida, Inc. (TCDA) today announced that it will present at the Goldman Sachs 40th Annual Health Care Conference on Wednesday, June 12, 2019 at 10:00 am PT. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Motley FoolTricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript
TCDA earnings call for the period ending March 31, 2019.
